Articles On Phylogica (ASX:PYC)

The S&P/ASX 200 Index (ASX: XJO) is having a day to remember on Thursday. In afternoon trade, the benchmark index is up a sizeable 1.55% to 7,873.9 points. Four ASX shares that have failed to follow the market higher today are listed b...

PYC Therapeutics (ASX:PYC) has announced that it has completed dosing in patient cohort 4 (75 μg dose) of the ongoing Single Ascending Dose study. 

PYC Therapeutics (ASX:PYC) says that one of its candidates for a blinding eye disease of childhood called Autosomal Dominant Optic Atrophy has demonstrated disease-modifying potential in ‘retina in a dish’ models.

The ASX200 closed the day up more than a per cent (1.08%). All sectors bar one finished in the green. Energy fell 1.5 per cent, but Healthcare lead gains, nearly two per cent (1.97%). Telecommunications followed, up 1.7 per cent. In t...

The ASX200 is up nearly a per cent – in a harmonious flow with futures predictions. Every sector – aside from energy – is in the green. Materials and industrials are having a particularly strong run, both up around 1.5 per cent.  I...

PYC Therapeutics (ASX:PYC) has completed Dose Range Finding (DRF) studies for its investigational drug, PYC-003, in Non-Human Primates (NHPs). The company’s PYC-003 drug is designed to address Autosomal Dominant Polycystic Kidney Diseas...

It’s been three consecutive months that US inflation data has come in higher than expected and, with that, predictions around interest rate cuts have been pushed back from July to November. Inflation rose from 3.2 per cent in February to...

PYC Therapeutics (ASX:PYC) has announced the successful closure of the institutional component of the entitlement offer to raise up to approximately $74.6 million. 

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.39% to 7,763.70. Markets @ Midday: Listen here at lunchtime or find all Market Matters Podcasts on Spotify...

PYC Therapeutics (ASX:PYC) has announced the results of a study conducted in three-dimensional human models derived from patients with end-stage renal failure due to autosomal dominant polycystic kidney disease.

PYC has developed a new drug candidate for the >5 million people worldwide[1] with Polycystic Kidney Disease (PKD) This drug candidate has demonstrated efficacy in human models derived from the kidneys of patients with end-stage renal f...

4DX surges more than 50pc after an update from the US PYC Therapeutic said its fourth drug candidate could be effective in kidney disease Pro Medicus has just signed a $20m, eight-year contract in the US   4D Medical up over 50pc Medtech...

PYC Therapeutics (ASX:PYC) has held a pre-IND meeting with the US FDA and announced it has agreed on a proposed pathway through clinical trials for its second investigational candidate.

PYC to take ADOA drug to human clinical trials Imugene provides update of its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial Cleo’s CleoDX Triage Test was published in ‘Cancer’ journal   PYC to commence human trials in 2024 after...

PYC Therapeutics (ASX:PYC) has announced that the Safety Review Committee (SRC) governing one of its phase 1 clinical trials has approved the escalation of dosing to patient cohort 2.

PYC Therapeutics (ASX:PYC) has completed dosing for patients in cohort one of the Platypus clinical trial.

ASX to open higher despite a drop on Wall Street Tonight’s US CPI data weighs on markets These two drugs could be the top selling drugs in history   The ASX 200 is set to open slightly higher on Thursday despite stocks falling in New York...

PYC receives Fast Track designation from the US FDA BCAL Diagnostics announces breakthrough results Nova Eye reports strong sales of iTrack Advance in the US   PYC Therapeutics granted Fast Track from US FDA Genetic diseases specialist PY...

PYC Therapeutics to advance to Phase 2 clinical trial Osteopore announced new CEO and non-executive director Incannex has as engaged Fortrea to manage its Phase 2/3 clinical trial   PYC to advance to Phase 2 after toxicology tests RNA dru...

PYC Therapeutics (PYC) doses the first patient with drug candidate VP-001, designed to treat blinding eye disease, Retinitis Pigmentosa Type 11 (RP11) The drug candidate is part of a phase one Single Ascending Dose study to assess the sa...

ASX falls 0.17% ahead of Chalmers dropping The Budget on the nation Financials led the pack today, adding 0.5% on an otherwise fairly moribund day Voltaic Strategic Resources climbs 188% on pre-assay lithium results at Ti Tree   The ASX h...

CardieX jumps 16pc after getting FDA clearance for CONNEQT Pulse CONNEQT Pulse is a world first multi-use vascular biometric monitor  Three ASX biotechs received clearance to commence studies   Health devices and wearables tech company Ca...

PYC Pharmaceuticals (PYC) lands approval from the US FDA to begin human trials of a new drug to treat the blinding eye disease Retinitis Pigmentosa (RP11) The genetic disease affects around one in every 100,000 people, and no other treat...

Rhythm plunged 45% this morning after announcing some TGA news The FDA has cleared PYC Therapeutics for first ever human trial on Retinitis Pigmentosa Type 11   Rhythm Biosciences (ASX: RHY) crashed 47% this morning after withdrawing its...

Sonic has taken a stake in Microba Immutep enters into second deal with Merck (Germany) and Pfizer  ImpediMed has a new CEO   Sonic takes strategic stake in Microba Giant healthcare stock Sonic Healthcare (ASX:SHL) has bought a stake in s...

PYC Therapeutics (PYC) completes single-dose toxicology of its investigational Retinitis Pigmentosa type 11 (RP11) treatment drug candidateAccording to PYC, the studies proved the drug was safe and well-tolerated at all dose levels assessed...

Highlights: The ASX 200 benchmark index closed up today, gaining 0.41% to end at 6,496.20 points. Over the last five days, the index has lost 4.56% and has shed 12.03% over the last 52 weeks. Materials was the best performing sector,...

PYC Therapeutics (PYC) adds a third drug program for the treatment of Phelan McDermid Syndrome (PMS) to its clinical pipelineThis new program follows in-vitro test results of PYC’s RNA therapeutic demonstrating an ability to correct the fau...

PYC Therapeutics and Race Oncology announce new RNA programs Recce Pharma accelerates its clinical programs Orthocell gets first purchase orders The race is hotting up to develop the next RNA-based drug discovery, as a couple of ASX liste...

The ASX 200 will open higher on Tuesday despite another selloff on Wall Street Investors dump risky assets as fears of recession grow FX market in turmoil Local shares are set to open higher on Tuesday. At 8am AEST, the ASX 200 October fu...

Highlights PYC Therapeutics has completed its pharmacokinetic (PK) studies in Non-Human Primates (NHPs) successfully. Results from PK studies will aid the progression of PYC’s investigational drug candidate for evaluation in human bein...

Biotech company PYC Therapeutics (PYC) has increased its stake in Vision Pharma to 93.5 per cent The company has agreed to subscribe to the full $10 million re-capitalisation undertaken by Vision The funds will be used to support Vision’...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

PYC Therapeutics (ASX:PYC) says it has completed a key translational milestone for its RNA platform by determining safe and well-tolerated doses of its co-lead drug candidate in non-human primates.

The hot debut of Evolution Energy Minerals (ASX:EV1) was not enough to save the ASX resources sector from falling today. The ASX 200 finished 0.67% down at 7,420 points. All sectors were down except tech, which gained 0.18%. In contrast, mo...

The ASX 200 Health Index (XHJ) is down by 0.30% at the time of writing, compared to the broader index which is down by 0.50%. Imugene (ASX:IMU) was up 4.35% in morning trading, after announcing partnership agreements  with Merck KGaA and Pf...

The ASX posted steady gains to start the week on Monday, with investors preferences leaning towards tech/consumer stocks and gold (unusual bedfellows) at the expense of the big banks and iron ore majors. Companies that specialise in the pre...

PharmAust has had a busy and productive quarter, setting the foundations for the commercialisation of its lead drug, monepantel. Clinical stage biotech company, PharmAust (ASX:PAA), has had a very productive last quarter, making progress an...

Summary The S&P/ASX200ended 60 points or 0.31% higher at 7,354. The index gained as much as 5% to hit an intraday high of 7,368. The tech sector declined 2.7%, led by BNPL players Afterpay and Zip Co. Australian shares closed...

Summary The S&P/ASX200 traded higher by 20 points or 0.27% at 7,352 by the afternoon. The index opened flat and gained as much 0.5% to hit a high of 7,368. Barring tech, all sectoral indices were trading in green, led by utilities...

The ASX finished in positive territory, although short of an all-time high. The ASX 200 closed 0.15 per cent higher at 7,293 having traded as high as 7,316 in intraday trade. Meanwhile, the ASX Emerging Companies Index retreated 0.40 per ce...

PYC Therapeutics (ASX:PYC), a company developing RNA therapeutics for inherited diseases, has announced it intends to accelerate a key program towards clinical trials.

The ASX 200 close 0.19 per cent lower than Friday at 7,282 points and the ASX Emerging Companies Index fell 0.53 per cent to 2,168 points. Tech shares gaining 2.8 per cent although other sectors were more muted – REITs was the next best per...

The PYC Therapeutics Ltd (ASX: PYC) share price has risen 170% in a year and 13% this month, following promising results in the development of a new lead drug, and the appointment of U.S. Biopharma Executive Jason Haddock to its board. PYC...

PYC Therapeutics (ASX:PYC), a biotechnology company developing precision RNA therapeutics, has announced the appointment of Dr Michael Rosenblatt to its board of directors.

The ASX finished in the red today dragged down by resources and energy. Materials and Energy stocks lost over 1 per cent each while Tech was the best sector gaining 0.70 per cent. Large caps fared worse than small caps with the ASX 200 losi...

Source: GoYong,Shutterstock Summary PYC Therapeutics’ investigational drug, VP-001, has restored function of the Retinal Pigment Epithelium. This achievement differentiates PYC’s RNA approach from Adeno-Associated Virus. PYC’s share...

PYC Therapeutics (ASX:PYC), a biotechnology company developing a new generation of precision RNA therapeutics, has announced the appointment of Dr Glenn Noronha as its chief development officer.

The PYC Therapeutics Ltd (ASX: PYC) share price leapt 9% higher to 18 cents today before slipping to trade at 17 cents by late afternoon. The share price gains came after the company announced that its lead drug was effective in all patien...